P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
| العنوان: | P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort |
|---|---|
| المؤلفون: | B Gros, N Plevris, N Constantine-Cooke, M Lyons, C O’Hare, C Noble, I D Arnott, G R Jones, C W Lees, L A A P Derikx |
| المصدر: | Journal of Crohn's and Colitis. 17:i876-i876 |
| بيانات النشر: | Oxford University Press (OUP), 2023. |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Gastroenterology, General Medicine |
| الوصف: | Background Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021). The primary endpoint of this study was to assess CT-P13 persistence following switch from SB2. Secondary endpoints included persistence stratified by the number of biosimilar switches (single, double and triple), effectiveness and safety. Methods We performed a prospective, observational, cohort study. All adult IBD patients on IFX biosimilar SB2 underwent an elective switch to CT-P13. Patients were reviewed in a virtual biologic clinic with protocol driven collection of clinical disease activity, CRP, faecal calprotectin (FC), IFX trough / antibody levels, and drug survival. Results 297 patients (CD n=196 [66%], UC/IBDU n=101, [34%]) were switched. This was the third, second and first IFX switch for 67 /297 (22.5%), 138 /297 (46.5%) and 92 /297 (31%) of the cohort respectively. Patients who underwent multiple IFX biosimilar switches had longer disease duration (p=0.0001) and IFX duration (p=0.0001) and were less often on combination therapy with an immunomodulator (p=0.0001). 90.6% of patients remained on IFX during a median follow-up of 7.5 months [6.8-8.1] (figure 1). The number of switches was not independently associated with IFX persistence after adjusting for confounders (table 1). Clinical (p=0.77), biochemical (CRP ≤5mg/mL; p=0.75) and faecal biomarker (FC Conclusion Multiple successive switches from IFX originator to biosimilars are effective and safe in patients with IBD, irrespective of the number of IFX switches. |
| تدمد: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjac190.0875 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::ecbbd426126abe3cdaa52f24bad0c781 https://doi.org/10.1093/ecco-jcc/jjac190.0875 |
| Rights: | CLOSED |
| رقم الانضمام: | edsair.doi...........ecbbd426126abe3cdaa52f24bad0c781 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18764479 18739946 |
|---|---|
| DOI: | 10.1093/ecco-jcc/jjac190.0875 |